Prospective assessment of the clinical benefit of a tailored cancer gene set built on a next-generation sequencing platform in patients with recurrent or metastatic head and neck cancer

AbstractWe performed a prospective trial to assess the clinical benefit of a tailored gene set built on a next-generation sequencing (NGS) platform in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Archived tumor tissue obtained from patients with recurrent or metastatic HNSCC was analyzed for variants by a tailored Comprehensive Cancer Gene set of 40 genes (CCG-40) performed on a NGS platform. These data were provided to clinicians to inform treatment decisions. The primary endpoint was clinical benefit (disease control) that resulted from selection and administration of a targeted therapy based on results of the CCG-40. Barriers to performance and implementation of the assay were recorded. Forty patients enrolled. Primary tumor sites included oropharynx (14), larynx/hypopharynx (14), oral cavity (9), and nasopharynx (3). The CCG-40 assay was performed in 23 patients (57.5%), but not in 17 patients due inadequate financial coverage (12) or insufficient tumor tissue (5). Potentially actionable tumor variants were identified in 3 patients (7.5%); all werePIK3CA variants. Due to inability to obtain access to candidate drugs (2) or rapid decline in performance status (1), none of these patients received targeted therapy informed by the CCG-40 results. The CCG-40 assay did not provide clinical benefit to the patients on this trial. Identification of limitations of the assay and barriers to the test ’s performance and application may be ...
Source: Medical Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

AbstractBackgroundPrevious studies have identified that patients withEGFR mutations tend to have better responses to targeted therapy, as well as chemotherapy; however, the effect of genetic alterations in terms of radiotherapy (RT) ‐related outcomes has not been fully assessed. We studied the impact of common non‐small cell lung cancer (NSCLC) genetic alterations (EGFR,ALK andKRAS) in relation to objective response rate (ORR) to RT in patients with brain metastases.MethodsFrom 2009 –2015, 153 patients with an available genotyping status were treated with whole‐brain irradiation (WBI) before receiving systemic ...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
ConclusionsEndostar delivered by CIV with CCRT may be a better option than IV in terms of potential survival and safety for unresectable stage III NSCLC.Key pointsSignificant findings of the study Endostar delivered by continuous intravenous pumping might achieve more favorable survival over intravenous injection and reduce adverse hematological reactions in patients with unresectable stage III NSCLC treated with Endostar combined with CCRT.What this study adds The administration route of recombinant human endostatin is also one key factor for survival and safety to consider when treating patients with unresectable stage III NSCLC.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
ConclusionsThe use of osimertinib immediately after nivolumab significantly increased the frequency of grade 3 or higher hepatotoxicity in patients with advanced NSCLC harboringEGFR mutation acquired T790M resistance.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Date: Friday, 02 28, 2020; Speaker: Jonathan Wasserman, Staff Physician, SickKids; BG 10-CRC; FAES 1&2
Source: NIH Calendar of Events - Category: American Health Source Type: events
To gain a better understanding of the factors that govern in vivo cellular recognition, artificial glycoproteins are created as biomimetic probes to study the influence of specific glycan assemblies to biodistribution. The principle aim of this Review is to present pioneering research that has driven artificial glycoprotein ‐based targeting and subsequent adaptations with potential therapeutic applications. AbstractAkin to a cellular “fingerprint,” the glycocalyx is a glycan‐enriched cellular coating that plays a crucial role in mediating cell‐to‐cell interactions. To gain a better understanding of the ...
Source: Small - Category: Nanotechnology Authors: Tags: Review Source Type: research
L-GILZ binds and inhibits nuclear factor κB nuclear translocation in undifferentiated thyroid cancer cells. J Chemother. 2020 Feb 18;:1-5 Authors: Marchetti MC, Cannarile L, Ronchetti S, Delfino DV, Riccardi C, Ayroldi E Abstract Proto-oncogene mutations and abnormal activation of mitogen-activated protein kinase (MAPK) signalling are recurrently found in thyroid cancers. Some thyroid neoplasms respond to drugs that inhibit MAPK pathway activation. Previously, we showed that pharmacological inhibition of MAPK in thyroid cancer cells inhibits cell proliferation and upregulates L-GILZ (long glucoco...
Source: Journal of Chemotherapy - Category: Cancer & Oncology Tags: J Chemother Source Type: research
This article is a continuation of the “Do You Know Your Guidelines” series, initiated by the Education committee of the American Head and Neck Society. Treatment guidelines for advanced head and neck squamous cell carcinoma are reviewed here, including the critical roles of radiotherapy, chemotherapy, and the recent application of immunotherapy agents. We will be limiting this discussion to include cancers of the oral cavity, oropharynx, hypopharynx, and larynx. It should be noted that much of the article pertains to human papillomavirus (HPV)‐negative oropharyngeal cancer where applicable, as HPV‐positive ...
Source: Head and Neck - Category: ENT & OMF Authors: Tags: PRACTICE GUIDELINES Source Type: research
Squamous cell carcinoma (SCC) is the most common malignancy of head and neck region arising from mucosal linings of the upper aerodigestive tract, comprising (1) nasal cavity and paranasal sinuses, (2) nasopharynx, (3) hypopharynx, larynx, and trachea, and (4) oral cavity and oropharynx [1,2]. Head and neck squamous cell carcinomas (HNSCC) are characterized by high morbidity and mortality rates and strong tendency to regional and distant metastasis [1–4]. These tumor characteristics depend on individual properties of neoplastic cells and tumor microenvironment, which is comprised by diverse inflammatory/immune cells ...
Source: Oral Oncology - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Squamous cell carcinoma arises from multiple anatomic subsites in the head and neck region. The risk factors for development of cancers of the oral cavity, oropharynx, hypopharynx, and larynx include tobacco exposure and alcohol dependence, and infection with oncogenic viruses is associated with cancers developing in the nasopharynx, palatine, and lingual tonsils of the oropharynx. The incidence of human papillomavirus–associated oropharyngeal cancer is increasing in developed countries, and by 2020, the annual incidence could surpass that of cervical cancer.
Source: Mayo Clinic Proceedings - Category: Internal Medicine Authors: Tags: Symposium on Neoplastic Hematology and Medical Oncology Source Type: research
Conclusions Preventable risk factor needs to be addressed. Counselling all patients and screening of high risk group along with health awareness creation may be effective in risk reduction.
Source: Clinical Epidemiology and Global Health - Category: Epidemiology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Genetics | Head and Neck Cancer | HNSCC | Hypopharyngeal Cancer | Laryngeal Cancer | Nasopharyngeal Cancer | Oral Cancer | Oral Cavity Cancer | Oropharyngeal Cancer | Skin Cancer | Squamous Cell Carcinoma